Log In
Print
BCIQ
Print
Print this Print this
 

Makena (hydroxyprogesterone caproate injection) (formerly Gestiva)

Also known as: 17P

  Manage Alerts
Collapse Summary General Information
Company Hologic Inc.
DescriptionLong-acting form of a naturally occurring progesterone, 17 alpha-hydroxyprogesterone caproate (17P)
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationUterine contractions
Indication DetailsPrevent preterm birth; Reduce risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of at least one spontaneous preterm birth
Regulatory Designation

U.S. - Accelerated Approval (Reduce risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of at least one spontaneous preterm birth);
U.S. - Orphan Drug (Prevent preterm birth)

Partner

Lumara Health Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today